Sun Protection Factor (SPF) Determination of Two Sunscreen-Containing Lip Balms

NCT04749459 | Completed Results

• 1 other identifier: 215232
• Study Type: interventional
• Target: 14
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this study is to determine the SPF of two test materials ChapStick Moisturizer, Classic Flavor and ChapStick Moisturizer, Strawberry Flavor using the methodology described in the International Standard Test Method. This static methodology also meets the requirements of the Australia/New Zealand standard.

Conditions

Sunscreening Agents

Outcome Measures

Primary Outcomes (1)

• Arithmetic Mean of Individual Sun Protection Factor (SPFi) Values

  Arithmetic mean of all valid SPFi values of each product on each participant was calculated from the individual Minimal Erythemal Dose (MED) on product treated (MEDp) test sites in relation to unprotected (MEDu) test sites 16-24 hrs after exposure to UVR. SPFi = MEDp/MEDu. No inferential statistical analysis was performed for this outcome. The MED is defined as the lowest dose of UVR that produces the first perceptible unambiguous erythema with defined borders appearing over most of the field of UVR exposure. The UVR exposure should be increased in geometric progression with 25% dose increment in relation to the expected SPF values. All individual SPF values were converted arithmetically to calculate SPF of test material (or control standard).

  Up to 24 hours post UVR exposure

Study Arms (3)

ChapStick Moisturizer, Classic Flavor

EXPERIMENTAL

This arm will include all the test sites on the participants back where ChapStick Classic Moisturizer (ANZ) will be applied.

Drug: ChapStick Moisturizer, Classic Flavor

ChapStick Moisturizer, Strawberry Flavor

EXPERIMENTAL

This arm will include all the test sites on the participants back where ChapStick Strawberry Moisturizer (ANZ) will be applied.

Drug: ChapStick Moisturizer, Strawberry Flavor

ISO 24444:2010 P2 Standard Sunscreen

ACTIVE COMPARATOR

This arm will include all the test sites on the participants back where ISO 24444:2010 P2 Standard Sunscreen will be applied.

Drug: ISO 24444:2010 P2 Standard Reference Sunscreen

Interventions

ChapStick Moisturizer, Strawberry Flavor DRUG

A single topical application of ChapStick Moisturizer, Strawberry Flavor will be applied to the appropriate 40 square centimeter (cm\^2) test site (on the back of each participants). This application shall provide a test material film of approximately 2.00 +/- 0.05 milligram per centimeter square (mg/cm\^2), using 80 +/-2 milligrams (mg) of material.

ChapStick Moisturizer, Strawberry Flavor

ChapStick Moisturizer, Classic Flavor DRUG

A single topical application of ChapStick Moisturizer, Classic Flavor will be applied to the appropriate 40 cm\^2 test site (on the back of each participants). This application shall provide a test material film of approximately 2.00 +/- 0.05 mg/cm\^2, using 80 +/-2 mg of material.

ChapStick Moisturizer, Classic Flavor

ISO 24444:2010 P2 Standard Reference Sunscreen DRUG

A single topical application of ISO 24444:2010 P2 Standard Sunscreen will be applied to the appropriate 40 cm\^2 test site (on the back of each participants). This application shall provide a test material film of approximately 2.00 +/- 0.05 mg/cm\^2, using 80 +/-2 mg of material.

ISO 24444:2010 P2 Standard Sunscreen

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participant must read and execute an informed consent document (that includes a HIPAA statement) indicating that the participant has been informed of all pertinent aspects of the trial before any assessment is performed;
• Participant must complete a Medical History Form (MHF) prior to their trial initiation;
• Participant must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures;
• Participant must agree not to expose their back to additional sunlight or tanning beds, as either can alter the test results;
• Participant must agree not to apply any topical skin-care product to the test sites during this trial;
• Male or female participants of childbearing potential must agree to use a highly effective method of contraception throughout the trial and for 14 days after the last application of assigned treatment. A participant is of childbearing potential if, in the opinion of the investigator, he/she is biologically capable of having children and is sexually active;
• Female participants of childbearing potential must be willing to comply with urine pregnancy testing requirements prior to initiation of trial testing procedures and as may be required for the duration of the trial;
• Participant must be considered dependable and capable of understanding and following directions;
• Participant must have self-perceived Fitzpatrick skin phototype I, II, or III:
• Skin Phototype Sunburn and Tanning History I Always burn easily; never tans II Always burns easily; tans minimally III Burns moderately; tans gradually; and
• Participant must have an Individual Typology Angle value \>28 degrees, determined by the Testing Facility by colorimetric methods, within 1 week of trial participation.

You may not qualify if:

• Participant is in ill health as determined by the Principal Investigator;
• Participant is an employee of the Clinical Division of the investigational site or a member of their immediate family;
• Participant is a GSK CH employee directly involved in the conduct of the trial or a member of their immediate family;
• Female participant is pregnant or intending to become pregnant over the duration of the trial or any female participant of childbearing potential who fails to produce a negative urine pregnancy test;
• Female participant who is lactating (self-reported);
• Participant using medication with photo-sensitizing potential;
• Participant has a history of adverse reactions or hypersensitivity to azo dyes, cosmetics, OTC drugs, or other topical personal care products;
• Participant taking medications other than birth control that could influence the purpose, integrity or outcome of the trial;
• Participant has used topical or systemic steroids, antihistamines, or antibiotics within 7 days of trial initiation or during the trial;
• Participant has used anti-inflammatory medications within 7 days of trial initiation or during the trial, that in the opinion of the PI, could interfere with the trial;
• Participant has used medication suspected of causing photobiological reactions (e.g., tetracyclines, thiazides, etc.), that has not been taken by the participant through a summer season;
• Participant has a dermatological condition;
• Participant has a history of abnormal response to the sun, or a condition such as lupus erythematosus or skin cancer;
• Participant uses tanning beds frequently;
• Participant whose test site was exposed to sunlight within the previous 4 weeks;

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (1)

GSK Investigational Site

Fairfield, New Jersey, 07004, United States

Location

Results Point of Contact

• Title: GSK Response Center
• Organization: GlaxoSmithKline

GSKClinicalSupportHD@gsk.com

866-435-7343

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 7, 2021
• First Posted: February 11, 2021
• Study Start: March 3, 2021
• Primary Completion: March 31, 2021
• Study Completion: March 31, 2021
• Last Updated: March 16, 2022
• Results First Posted: March 16, 2022

Record last verified: 2022-01

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF, CSR
• Time Frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
• Access Criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension can be granted, when justified, for up to another 12 months.

Locations

US (1)